Could Jardiance be a breakthrough for Type II diabetes? Reduce cardiovascular deaths?

Let’s hope this isn’t hype.

ttp://acsh.org/2015/08/another-historical-moment-for-diabetes/

Advertisements

One response to “Could Jardiance be a breakthrough for Type II diabetes? Reduce cardiovascular deaths?

  1. @john1282
    1. Press release only; details to be forthcoming

    2. All of these studies have the major major confounding factor of the participants being mostly fatties (80-85% of type 2s). SO…You take bad lifestyle people and put them on *any* regimen, and you will probably get “results.”

    “The study was designed to assess the effect of Jardiance (empagliflozin) (10mg or 25mg once daily) added to standard of care compared with placebo added to standard of care on CV events in adults with T2D at high risk of CV events and with less than optimised blood glucose control. The study was designed to first test for non-inferiority and then for superiority.”

    Of course, those in the study were already sick, and that is the problem with around 100% of all studies done on type 2. What does “high risk of CV events” mean in a practical and quantitative sense?

    3. Study compared Jardiance to a placebo. Big deal? How about comparing it to other drugs?

    4. And BTW, what if the “standard of care” is making them worse?

    5. I will withhold final judgment until the details appear, but this seems like just more crapola. And why no mention of the FDA warning?

    http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s